10 reasons you need an eGlycemic Management System®

Glycemic management has ripple effects throughout the hospital.

Insulin has a direct impact on patient health. But did you know that problems with insulin management can also impact key quality indicators, clinician workflows and your bottom line?

An eGlycemic Management System (eGMS) can help you improve the safety and effectiveness of insulin therapy — and the positive effects of this system reach farther than you might expect.

1. Insulin therapy is becoming more important.

45% of U.S. adults have diabetes or prediabetes, and the numbers are increasing.\(^1\)

38% of inpatients (with or without diabetes) require insulin therapy during their stay.\(^2\)
2. Glycemic management issues impact key quality indicators.

Patients who experience hypoglycemia and hyperglycemia have higher 30-day readmission rates and a longer average length of stay. eGMS usage has been proven to significantly improve these metrics.

**ACTUAL RESULTS USING GLYTEC’S EGMS:**

| 3.2 days reduction in average length of stay | 36-68% reduction in 30-day readmissions for AMI, CHF and CABG patients |

3. eGMS usage can help get patients into target blood glucose range faster — and stay there.

![Graph showing blood glucose levels over time](image)

4. CMS is working on a measure that will incentivize hospitals to reduce the incidence of hypoglycemia.

eGMS usage has been shown to lead to a 99.8% reduction in frequency of severe hypoglycemia.
5. **Patients who experience hypoglycemia cost more to treat.**

The average cost of care for patients who experience hypoglycemia is **$5,000-$10,000 higher** than those with normal glycemia.\(^7\)

eGMS usage has been proven to save hospitals **millions per year** by reducing cost of care.\(^3\)

6. **Sliding scale insulin therapy is ineffective and potentially dangerous.**

“Use of only a sliding scale insulin regimen in the inpatient hospital setting is strongly discouraged.”

*American Diabetes Association, 2020*\(^8\)

Glytec’s eGMS has been proven to help **drive the adoption of basal-bolus insulin therapy** among clinicians.\(^3\)

7. **Paper protocols for insulin dosing are time-consuming and prone to transcription errors.**

Glytec’s eGMS can be **integrated with EMR systems** to automatically import data, speeding up workflows and reducing errors.

8. **eGMS is available throughout the continuum of care.**

- **Hospital**: Emergency Department Glucommander IV, ICU Glucommander IV, Stepdown/Floor Glucommander Transition Glucommander SubQ
- **Transition**: Discharge Glucommander H2H
- **Home**: Ongoing Insulin Management Glucommander H2H, Outpatient Solution
9. **59% of US Hospitals report not having the ability to extract or analyze glucose data, known as glucometrics⁹**

   eGMS can provide advanced analytics of organizational glycemic management performance. Set goals and expectations for quality and performance improvement and measure progress with the GlucoMetrics® module.

10. **When integrated with a laboratory information system, eGMS can provide automatic alerts regarding at-risk patients.**

   Continuous, real-time surveillance flags patients throughout the hospital with persistent hyperglycemia, which allows providers to ensure orders for IV or SubQ insulin are placed before negatively impacting patient outcomes.

Contact Glytec to learn how eGMS could help your hospital.
References


The eGlycemic Management System® is a modularized solution for glycemic management across the care continuum that includes Glucommander™. Glucommander™ is a prescription-only software medical device for glycemic management intended to evaluate current as well as cumulative patient blood glucose values coupled with patient information including age, weight and height, and, based on the aggregate of these measurement parameters, whether one or many, recommend an IV dosage of insulin, glucose or saline or a subcutaneous basal and bolus insulin dosing recommendation to adjust and maintain the blood glucose level towards a configurable physician-determined target range. Glucommander™ is indicated for use in adult and pediatric (ages 2-17 years) patients. The measurements and calculations generated are intended to be used by qualified and trained medical personnel in evaluating patient conditions in conjunction with clinical history, symptoms, and other diagnostic measurements, as well as the medical professional’s clinical judgement. No medical decision should be based solely on the recommended guidance provided by this software program.

Glucommander™ is only available for use in the United States.

This content is only intended for use in the United States.